Welcome to our dedicated page for Nemaura Med news (Ticker: NMRD), a resource for investors and traders seeking the latest updates and insights on Nemaura Med stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nemaura Med's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nemaura Med's position in the market.
Nemaura Medical (NASDAQ: NMRD) announces it will present at the Virtual Diabetes Technology Meeting on November 12, 2020. CEO Dr. Faz Chowdhury will discuss “CGM Usage for the Management and Reversal of Type 2 diabetes.” This year's event is virtual due to COVID-19, connecting technology developers for diabetes management solutions. Nemaura plans to launch proBEAT™ in December 2020, a non-invasive glucose monitor that provides AI-driven feedback to help manage diabetes. With over 88 million pre-diabetic and 25 million diabetic patients in the U.S., Nemaura aims to address this health crisis.